-
Lepu Scientech Secures NMPA Approval for MemoSORB Biodegradable Atrial Septal Defect Occluder
•
Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received a medical device license from China’s National Medical Products Administration (NMPA) for its innovative MemoSORB biodegradable atrial septal defect occluder. This cutting-edge device offers significant advantages over traditional nitinol occluders by markedly reducing inflammatory responses,…
-
Lepu Scientech Secures NMPA Approval for RF Lance, Advancing Atrial Septal Puncture Technology
•
Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading medical technology company based in China, has announced that it has obtained a medical device license from the National Medical Products Administration (NMPA) for its RF Lance, a novel disposable radiofrequency atrial septal puncture needle. This product is designed…
-
Lepu ScienTech Reports 33% Revenue Growth in 2023 Interim Report
•
Lepu ScienTech Medical Technology (Shanghai) Co., Ltd, (HKG: 2291) a China-based medical technology company, has released its 2023 interim report, showcasing significant financial growth. The company reported revenues of RMB 165.9 million, marking a 33.0% increase year-on-year (YOY). Net profits also saw a substantial rise, surging by 213.7% YOY to…
